|
|
 |
|
Viewing report
|
|
|
|
Top 50 Biotechnology Companies & Their Pipelines 2011
UBM Canon, Aug 2011, Pages: 80
The recent acquisition of Genzyme by Sanofi and the announcement that Teva will acquire Cephalon demonstrate that the gap between the pharmaceutical and biotechnology industries continues to narrow. Companies conduct aggressive mergers as pipelines and new drug approvals lack blockbuster options, the patent cliff grows, and U.S. healthcare reform takes shape. Biotech companies in the industry's traditional centers of Australia, Canada, Europe, and the United States had a record-breaking 2010 with a 30% net profit increase compared to 2009. Companies in these markets reportedly combined for an aggregate net profit of $4.7 billion. Excluding Australia, biotech players in the other three markets raised $25 billion in capital during 2010.
In 2010, the top 10 biotech companies had combined revenue of $77.85 billion, up from $75.59 billion in 2009. The top 10 companies per 2010 revenue were Roche, Amgen, Gilead Sciences, Biogen Idec, UCB, Genzyme, CSL, Celgene, Cephalon, and Actelion. Switzerland's Roche generated SFr47.5 billion in revenue in 2010 with overall R&D investments totaling SFr10.0 billion. Roche is an innovator of products and services used in the early detection, prevention, diagnosis and treatment of several diseases. The company's mission is to create additional value in healthcare by focusing its expertise in diagnostics and pharmaceuticals. As the largest biotech company globally, Roche medicines span across areas such as oncology, virology, inflammation, metabolism, and CNS. Since its initial U.S. approval in 2004 for the treatment of colorectal cancer, the blockbuster drug Avastin has grown to include indications for several types of cancers.
The drug is approved in the United States and Europe for the treatment of advanced stages of colorectal cancer, breast cancer, non-small cell lung cancer, and kidney cancer. Avastin is Roche's top-selling product and was the No. 7 seller among prescription medicines worldwide in 2010, earning $6.19 billion.
The following information is included for the top 50 biotechnology companies (which were determined based on their healthcare revenue generated during 2010):
- Each products’ chemical or substance composition, intended indication, clinical status, region of development, and developer/marketer
- Pipeline status details preclinical development, Phase I, Phase II, Phase III, and awaiting approval
- Region of development includes the U.S., Europe, and Japan
- Select 2010 and 2009 financial data such as revenue, net income, earnings per share, and R&D expenditure
An overview highlighting the top 10 biotech companies and some of their most-promising products.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
